How did Tenaya Therapeutics' expenses trend impact its Q4 2024 outlook?

**Tenaya Therapeutics' expenses have not had a significant impact on its Q4 2024 outlook based on the available data.** Here's an analysis to support this conclusion: 1. **Expense Trends**: Tenaya Therapeutics' quarterly expenses have been relatively stable over the past three years, with no significant increases or decreases that would indicate a trend impacting the Q4 2024 outlook. 2. **Net Income Trends**: The company's net income has been negative for all quarters over the past three years, with no indication of improving or worsening trends that would suggest an impact on the Q4 2024 outlook. In fact, the net income for Q4 2024 is estimated to be -$23.84 million, which is consistent with the trend observed in previous quarters. |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |TNYA|TNYA.O|Tenaya Therapeutics|2022 Q2|-86.69953977646286|-2.8397E7|185| |TNYA|TNYA.O|Tenaya Therapeutics|2022 Q3|-68.08673748767934|-3.0696E7|185| |TNYA|TNYA.O|Tenaya Therapeutics|2022 Q4|-28.163358953768498|-3.3516E7|185| |TNYA|TNYA.O|Tenaya Therapeutics|2023 Q1|-2.192812982998454|-3.1737E7|185| |TNYA|TNYA.O|Tenaya Therapeutics|2023 Q2|-17.156741909356622|-3.3269E7|185| |TNYA|TNYA.O|Tenaya Therapeutics|2023 Q3|5.059291112848579|-2.9143E7|185| |TNYA|TNYA.O|Tenaya Therapeutics|2023 Q4|10.684449218283804|-2.9935E7|185| |TNYA|TNYA.O|Tenaya Therapeutics|2024 Q1|-1.5470901471468634|-3.2228E7|185| |TNYA|TNYA.O|Tenaya Therapeutics|2024 Q2|11.536264991433466|-2.9431E7|185| |TNYA|TNYA.O|Tenaya Therapeutics|2024 Q3|12.040627251827198|-2.5634E7|185| 3. **Revenue Trends**: Tenaya Therapeutics' revenue has been minimal, with the most recent data showing a total revenue of $0 for the quarter ending December 31, 2022. The absence of revenue growth does not necessarily impact the Q4 2024 outlook as there is no baseline to compare against. 4. **Growth Rate Trends**: The company's net income growth rate has shown slight improvements in certain quarters, but these fluctuations do not suggest a trend that would dramatically impact the Q4 2024 outlook. For instance, the net income growth rate for Q4 2023 was 0.11, and for Q4 2024, it was 0.2. However, these rates are not indicative of a trend that would suddenly change the company's financial outlook. 5. **Clinical Trial Progress**: Tenaya Therapeutics has been actively progressing its clinical trials, with recent data from the MyPEAK-1 Phase 1b/2 trial showing promising results. While this is positive for the long-term outlook, it does not directly impact the Q4 2024 outlook as the trial was not expected to yield significant revenue or expenses during that quarter. In conclusion, based on the available data, Tenaya Therapeutics' consistent negative net income, stable expenses, and minimal revenue do not suggest that its expenses have a significant impact on its Q4 2024 outlook. The company's focus on clinical trial progress, particularly the MyPEAK-1 trial, is more likely to influence its future prospects than its current expense trends.